Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Recombinant or stably-transformed bacterium encoding one or...
Reexamination Certificate
1999-05-25
2003-08-05
Devi, S. (Department: 1645)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Recombinant or stably-transformed bacterium encoding one or...
C424S234100, C424S093480, C424S093400, C424S093200, C424S184100, C435S069100, C435S069300, C435S252100, C435S253100, C435S320100, C435S029000, C435S091400, C435S091420
Reexamination Certificate
active
06602506
ABSTRACT:
FIELD OF INVENTION
The present invention relates to recombinant Yersinia and the use thereof for delivery of proteins into eukaryotic cells.
BACKGROUND
Bacteria of the genus Yersinia cause diseases in humans and rodents ranging from enteritis and lymphadenitis to plague. The genus Yersinia encompasses three species:
Yersinia enterocolitica
, which is the most prevalent Yersinia species in humans and causes a broad range of gastro-intestinal syndromes;
Yersinia pseudotuberculosis
, which causes adenitis and septicaemia; and
Yersinia pestis
, which is the causative agent of plague.
In spite of the differences in the infection routes, these three species of Yersinia share a common capacity to resist the non-specific immune response of the human or rodent host and to proliferate in the host lymphatic tissues. Anatomo-pathological examinations revealed that Yersinia are not detected inside the inflammatory or parenchymal cells of the infected animals (Simonet et al. (1990)
Infect. Immun
. 58: 841-845). Consistent with these in vivo observations, Yersinia are resistant to phagocytosis in vitro by macrophages and polymorphonuclear leukocytes. See review by Cornelis et al. (1997)
Mol. Microbiol
. 23(5): 861-867. Yersinia enterocolitica also has the capacity to enter certain cultured epithelial cells, a process generally referred to as invasion (Miller et al. (1988)
Infect. Immun
. 56: 1242-1248).
Genetic studies revealed that the virulence of Yersinia is determined by a 70 kb plasmid (pYV), which encodes and governs the production of a set of proteins called Yops (for Yersinia outer proteins). These Yops form an integrated anti-host system that allows the extracellular adhesion of Yersinia to the surface of host cells and the subsequent injection of a set of toxic effector proteins into the host cell's cytosol. Recent studies further revealed that such an anti-host system, also called “Yersinia virulon”, is composed of the following four elements: (i) a contact or type III secretion system called Ysc, which is devoted to the secretion of Yop proteins out of the bacterial cells; (ii) a set of “translocators” for translocating the effector proteins into the eukaryotic host cells, which consist of YopB, YopD and possible other proteins such as LcrV; (iii) a control element and recognition system (YopN and LcrG); and (iv) a set of “effector proteins” including YopE, YopH, YopO/YpkA, YopM and YopP/YopJ, which are injected (or translocated) into the eukaryotic host cells and disrupt the functions of such host cells. Transcription of these genes is controlled both by temperature and by contact with a eukaryotic cell. See review by Cornelis et al. (1997).
The effector proteins disrupt the function of host cells in a number of ways. The 23 kd YopE is a cytotoxin that disrupts the actin-microfilament structure of cultured Hela cells (Rosqvist et al. (1990)
Mol. Microbiol
. 4: 657-667; Rosqvist et al. (1991)
Infect. Immun
. 59: 4562-4569). The 51 kd YopH is a protein tyrosine phosphatase (PTPase) related to eukaryotic PTPases, which acts on tyrosine-phosphorylated proteins of infected macrophages (Hartland et al. (1994)
Infect. Immun
. 62: 4445-4453). Presumably as a result of this action, YopH inhibits bacterial uptake and oxidative burst by cultured macrophages (Rosquvist et al. (1988)
Infect. Immun
. 56: 2139-2143; Bliska et al. (1995)
Infect. Immun
. 63: 681-685). YopO (or YpkA) is an 81 kd serine/threonine kinase, which is targeted to the inner surface of the plasma membrane of the eukaryotic cell and might function to interfere with the signal transduction pathway of the eukaryotic cell (Hakansson et al. (1996)
Mol. Microbiol
. 20: 593-603). YopM is an acidic 41 kd protein having 12 leucine-rich repeats, which suggests that YopM might bind thrombin and interfere with platelet-mediated events of the inflammatory response (Leung et al. (1989)
J. Bacterial
. 171: 4623-4632). YopP is involved in the induction of apoptosis in macrophages (Mills et al. (1997)
Proc. Acad. Natl. Sci. USA
94: 12638-12643).
The molecular structures of these effector proteins have been investigated to determine the elements in each effector protein that are required for their secretion and translocation. For this purpose, hybrid proteins have been engineered by fusing truncated Yop effector proteins of different length with certain reporter enzymes such as the calmodulin-activated adenylate cyclase domain (or Cya) of the
Bordetella pertussis
cyclolysin. Successful secretion and/or translocation events could be detected by assays based on the enzymatic activity of the reporter protein. Sory et al. disclose, by applying this approach, that YopE and YopH of
Y. enterocolitica
are modular proteins composed of three domains, i.e.,an N-terminal domain required for secretion, a translocation domain required for translocation into cells, and a C-terminal catalytic domain responsible for the toxic effector activity. Sory et al. (1995)
Proc. Natl. Acad. Sci. USA
92: 11998-12002. The same domain organization has been demonstrated for YopM of
Y. enterocolitca
(Boland et al. (1996)
EMBO J
. 15: 5191-5201).
The present invention provides recombinant Yersinia for safe delivery of proteins into eukaryotic cells. Such Yersinia are deficient in the production of functional effector proteins, but are endowed with a functional secretion and translocation system. The present invention further provides expression vectors for use in combination with such mutant Yersinia for safe and efficient delivery of desired proteins into eukaryotic cells. This approach is useful not only for studying the function of a given protein, but also for designing therapeutic approaches. For example, a protein of a pathogenic origin, e.g., a tumor associated protein, a parasite antigen, or a viral antigen, can be delivered using the recombinant Yersinia of the present invention into antigen presenting cells for inducing an immune response specific for such a protein.
Most progressively growing neoplastic cells express potentially immunogenic tumor-associated antigens (TAAs), also called tumor rejection antigens (TRAs). TRAs, like other antigenic epitopes, are presented at the surface of tumor cells by MHC molecules and have been shown to induce a CTL response in vivo and in vitro. See, for example, van der Bruggen et al. (1991)
Science
254: 1643-1647. However, such TRA-expressing tumor cells do not provoke reliable anti-tumor immune responses in vivo that are capable of controlling the growth of malignant cells. Boon et al. (1992)
Cancer Surveys
13: 23-37; T. Boon (1993)
Int. J. Cancer
54: 177-180; T. Boon (1992)
Advances Cancer Res.
58: 177-209.
A number of genes have been identified that encode tumor rejection antigen precursors (or TRAPs), which are processed into TRAs in tumor cells. Such TRAP-encoding genes include members of the MAGE family, the BAGE family, the DAGE/Prame family, the GAGE family, the RAGE family, the SMAGE family, NAG, Tyrosinase, Melan-A/MART-1, gp100, MUC-1, TAG-72, CA125, mutated proto-oncogenes such as p21ras, mutated tumor suppressor genes such as p53, tumor associated viral antigens such as HPV16 E7. See, e.g., review by Van den Eynde and van der Bruggen (1997) in
Curr. Opin. Immunol
. 9:684-693, Sahin et al. (1997) in
Curr. Opin. Immunol
. 9:709-716, and Shawler et al. (1997)
Advances in Pharmacology
40: 309-337 Academic Press, Inc.: San Diego, Calif. The identification of these genes has allowed recombinant production of TRAs or TRAPs which may be subsequently used as vaccines to treat various cancerous conditions.
The present invention contemplates the use of recombinant Yersinia for delivery of desired proteins into eukaryotic cells. Particularly, the recombinant Yersinia of the present invention are useful for delivery of proteins or derivatives thereof to antigen presenting cells. In accordance with the present invention, antigen presenting cells upon receiving the delivery, present antigenic epitopes which can be recognized by T cells. Thus, the recombinant Yersinia of the present in
Boland Anne M.
Boon-Falleur Thierry R.
Cornelis Guy R.
van der Bruggen Pierre B.
Devi S.
Ludwig Institute for Cancer Research
Scully Scott Murphy & Presser
LandOfFree
Delivery of proteins into eukaryotic cells with recombinant... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Delivery of proteins into eukaryotic cells with recombinant..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Delivery of proteins into eukaryotic cells with recombinant... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3074669